New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution
暂无分享,去创建一个
C. Contag | S. Thorne | A. Matin | S. Lynch | Y. Barak | D. Ackerley | Abdul Matin
[1] Shiladitya Sengupta,et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system , 2005, Nature.
[2] A. Matin,et al. ChrR, a Soluble Quinone Reductase of Pseudomonas putida That Defends against H2O2* , 2005, Journal of Biological Chemistry.
[3] D. Kerr,et al. NITROREDUCTASE: A PRODRUG‐ACTIVATING ENZYME FOR CANCER GENE THERAPY , 2004, Clinical and experimental pharmacology & physiology.
[4] A. Matin,et al. Mechanism of chromate reduction by the Escherichia coli protein, NfsA, and the role of different chromate reductases in minimizing oxidative stress during chromate reduction. , 2004, Environmental microbiology.
[5] B. Stoddard,et al. Alanine-scanning mutagenesis reveals a cytosine deaminase mutant with altered substrate preference. , 2004, Biochemistry.
[6] W. Denny,et al. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase. , 2004, Journal of medicinal chemistry.
[7] A. Matin,et al. Chromate-Reducing Properties of Soluble Flavoproteins from Pseudomonas putida and Escherichia coli , 2004, Applied and Environmental Microbiology.
[8] O. Greco,et al. Prodrugs in genetic chemoradiotherapy. , 2003, Current pharmaceutical design.
[9] S. White,et al. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. , 2003, Cancer research.
[10] W. Denny. Nitroreductase-based GDEPT. , 2002, Current pharmaceutical design.
[11] W. Fisher,et al. Current Progress in Suicide Gene Therapy for Cancer , 2002, World Journal of Surgery.
[12] D. Ross,et al. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. , 2001, Biochemical pharmacology.
[13] S. White,et al. The structure of Escherichia coli nitroreductase complexed with nicotinic acid: three crystal forms at 1.7 A, 1.8 A and 2.4 A resolution. , 2001, Journal of molecular biology.
[14] K. Danenberg,et al. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors. , 2001, Clinical Cancer Research.
[15] D. Kerr,et al. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector‐mediated expression of E. coli nitroreductase , 2000, International journal of cancer.
[16] A. Matin,et al. Purification to Homogeneity and Characterization of a Novel Pseudomonas putida Chromate Reductase , 2000, Applied and Environmental Microbiology.
[17] D. Kerr,et al. Virus-directed enzyme prodrug therapy using CB1954. , 1999, Anti-Cancer Drug Design.
[18] C. Contag,et al. Visualizing the kinetics of tumor-cell clearance in living animals. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[19] N. W. Davis,et al. The complete genome sequence of Escherichia coli K-12. , 1997, Science.
[20] W. Stemmer. DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[21] F. Arnold,et al. Tuning the activity of an enzyme for unusual environments: sequential random mutagenesis of subtilisin E for catalysis in dimethylformamide. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[22] W. D. de Vos,et al. Improved site-directed mutagenesis method using PCR. , 1991, Nucleic acids research.
[23] A. Charbit,et al. High efficiency transformation of Salmonella typhimurium and Salmonella typhi by electroporation , 1990, Molecular and General Genetics MGG.